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ABSTRACT
Aberrant stem cell-like gene regulatory networks
are a feature of leukaemogenesis. The ETS-related
gene (ERG), an important regulator of normal
haematopoiesis, is also highly expressed in T-ALL
and acute myeloid leukaemia (AML). However, the
transcriptional regulation of ERG in leukaemic cells
remains poorly understood. In order to discover tran-
scriptional regulators of ERG, we employed a quan-
titative mass spectrometry-based method to iden-
tify factors binding the 321 bp ERG +85 stem cell
enhancer region in MOLT-4 T-ALL and KG-1 AML
cells. Using this approach, we identified a number
of known binders of the +85 enhancer in leukaemic
cells along with previously unknown binders, in-
cluding ETV6 and IKZF1. We confirmed that ETV6
and IKZF1 were also bound at the +85 enhancer in
both leukaemic cells and in healthy human CD34+
haematopoietic stem and progenitor cells. Knock-
down experiments confirmed that ETV6 and IKZF1
are transcriptional regulators not just of ERG, but
also of a number of genes regulated by a densely in-
terconnected network of seven transcription factors.
At last, we show that ETV6 and IKZF1 expression
levels are positively correlated with expression of a
number of heptad genes in AML and high expression
of all nine genes confers poorer overall prognosis.
INTRODUCTION
The differentiation of haematopoietic stem cells (HSCs)
into lineage-committed haematopoietic cells is driven by
gene expression patterns that are tightly controlled by tran-
scription factors (1,2). The faithful, cell type-specific, ex-
pression of these transcription factors enables a proper ex-
ecution of the normal haematopoietic differentiation pro-
gram. However, aberrations in gene regulatory networks
frequently occur in leukaemias, leading to impaired differ-
entiation and an expansion of an immature cell population
(3,4). Chromosome translocations involving transcription
factors or alterations in the chromatin structure of gene reg-
ulatory regions upstream of genes encoding haematopoietic
transcription factors are frequently observed in leukaemias
(5). Furthermore, mutations within coding sequences of
transcription factors with important roles in developmen-
tal haematopoiesis, such as RUNX1 and CEBPA, also oc-
cur in various forms of leukaemia (6). Intriguingly, the gene
expression signatures of leukaemic cells overlap more with
normal HSCs than with those of the more differentiated
progenitor cells from which they arise (7). A number of
oncogenes have been shown to promote self-renewal or con-
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fer a stem cell-like gene expression profile in leukaemic cells
(8). However, it remains poorly understood whether there
might be differences in the underlyingmechanisms bywhich
leukaemic cells initiate and/ormaintain a stem cell-like phe-
notype. Uncovering these differences has significant clini-
cal implications, as it would pave the way for therapies that
could specifically target leukaemic cells whilst sparing nor-
mal cells by leveraging underlying differences (9).
One contributing factor for our lack of understanding of
the regulation of transcriptional networks in leukaemic cells
is the limitation of the most commonly used technique in
studying transcription factor––DNA interactions, the chro-
matin immunoprecipitation (ChIP) assay. In ChIP, proteins
are formaldehyde cross-linked to in vivo bound regions of
chromatin and an antibody specific to the protein of inter-
est is used to immunoprecipitate the protein and isolate re-
gions of the genome that are bound by that protein. ChIP
has been an invaluable tool in determining genome-wide
binding of many transcription factors and has contributed
much to efforts in re-constructing gene regulatory networks.
However it has an inherent limitation as an a priori dis-
covery method to identify new proteins bound to a regula-
tory region, as it requires the use of antibodies against pre-
determined proteins. In addition, as there are only a lim-
ited number of highly-specific, ChIP-grade antibodies avail-
able against transcription factors, there is a constraint to
the number of transcription factors that can be practically
studied by ChIP. Furthermore, despite the development of
modified ChIP techniques such as sequential ChIP, study-
ing multi-protein complexes with these methodologies re-
mains very challenging. For these reasons, utilizing a com-
plementary discovery method to study factors involved in
regulating gene expression in leukaemic cells would improve
our knowledge of the drivers of the aberrant stem cell-like
transcriptional program in leukaemias.
One alternative to ChIP is digital genomic footprint-
ing (10), a technique that can reveal all the regions in the
genome that are bound by proteins but which does not re-
veal the identities of these bound proteins. In silico meth-
ods may be combined with digital genomic footprinting to
predict which transcription factors that might be bound at
these regions based on the presence of conserved DNA se-
quence motifs. However, a lack of experimentally validated
data and insufficient knowledge of the binding motifs for
the majority of the ∼1200 transcription factors encoded by
the human genome, limit the power of such methods. In ad-
dition, as multiple members within a family of closely re-
lated transcription factors can bind the same motif, it re-
mains difficult to unequivocally determine which proteins
might be bound at a given motif. Furthermore, these meth-
ods can only inform us of factors that directly bind DNA
sequences but not of those that bind indirectly through
protein-protein interactions. New technological advances
in mass spectrometry (MS) provide a means to overcome
many of these limitations (11,12). In recent years, a num-
ber of groups have coupled traditional DNA affinity chro-
matography with sensitive MS methods to study DNA–
protein interactions (13–15). Methods incorporating stable
isotope labelling by amino acids in culture (SILAC), along
withDNApull downs andMShave been developed to study
proteins binding to DNA (13) and to chromatin (16). These
approaches have been extended to identify allele-specific
binding of transcription factors to single nucleotide poly-
morphisms (17) as well as to discover specific binders of
methylated and hydroxymethylated DNA (18,19).
As a first step towards further elucidating differences
in the gene regulatory networks driving a stem cell-like
program in leukaemic cells, we adapted a SILAC-based
proteomics method (13), hereafter referred to as rever-
seChIP, to characterize the transcriptional regulation of
ERG in leukaemic cells. ERG is an important regulator of
haematopoiesis (20,21) which is also highly expressed in
leukaemias. Murine models over-expressing ERG develop
T-ALL and acute myeloid leukaemia (AML) (22–24) while
high ERG expression is an independent predictor of poor
outcomes in subsets of T-ALL and AML patients (25–27).
Thus, while necessary for normal haematopoiesis, the fail-
ure to properly regulate ERG transcription contributes to
leukaemogenesis. Previous ChIP studies have revealed that
the binding of a heptad of transcription factors to the ERG
+85 stem cell enhancer upstream regulates high ERG ex-
pression in healthy haematopoietic stem and progenitor
cells (HSPCs) (2,28) as well in leukaemic cells (22,29). How-
ever, it is unknown if the heptad represents the entire com-
plement of factors contributing to dysregulated ERG ex-
pression in leukaemic cells or whether additional factors
might also be involved. By performing reverseChIP on the
ERG +85 enhancer in T-ALL and AML cells, we have iden-
tified two new factors, ETV6 and IKZF1, as previously un-
known binders and regulators of this region in leukaemic
cells.We confirmed that these factors bind the +85 enhancer
in vivo by ChIP, and used siRNA-mediated knockdown ex-
periments to show that they promote high ERG expression
in leukaemic cells. Consistent with our findings, we also
discovered a positive correlation between high ETV6 ex-
pression and ERG expression in AML patients. Extending
our studies to healthy CD34+ HSPCs, we found by ChIP
that both ETV6 and IKZF1 are enriched at a number of
haematopoietic enhancers, including the +85 enhancer. In
summary, by using a quantitative proteomics-based discov-
ery approach that is complementary to ChIP, we have dis-
covered new transcriptional regulators of ERG.
MATERIALS AND METHODS
Cell culture
MOLT-4 and KG-1 leukaemic cell lines were grown in
RPMI 1640 medium containing 10% Fetal Bovine Serum
(FBS), 1% Glutamax and 1% penicillin-streptomycin.
For SILAC experiments, cells were cultured in RPMI
1640 media (Thermo Fisher Scientific) containing either
unlabelled/natural lysine and arginine (‘light’) or with L-
Arginine.HCl (13C6, 99%) and L-Lysine.2HCl (13C6, 99%),
designated as ‘heavy’ media. Isotope-labelled amino acids
were purchased from Cambridge Isotope Laboratories Inc.
(MA,USA). Cells were cultured in ‘heavy’ media for at least
six passages for SILAC experiments. For CD34+ HSPCs,
mobilized apheresis samples from normal donors were ob-
tained from the Prince of Wales Hospital. The CD34+ frac-
tion was purified using an automated CliniMACS cells sep-
aration system (Miltenyi Biotec, Bergist Gladbach, Ger-
many). Collection of HSPCs from normal donors was ap-
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proved by the Ethics Committee at the Prince ofWales Hos-
pital and endorsed by the Human Research Ethics com-
mittee at the University of New South Wales, Sydney, Aus-
tralia.
ReverseChIP
After metabolic labelling of cells by SILAC, nuclear protein
extracts were prepared from labelled (‘heavy’) or unlabelled
(‘light’) cultures using theNE-PERKit (Thermo Scientific).
Heavy nuclear extracts were assessed byMS to ensure com-
plete labelling of proteins. The wild-type and mutant DNA
baits were generated by polymerase chain reaction (PCR)
using a 5′-biotinylated forward primer and an unbiotiny-
lated reverse primer from plasmids containing the wild-type
ERG +85 enhancer or mutant constructs, which had been
previously generated (22). PCR amplicons were purified us-
ing the Qiaquick PCR Purification kit (Qiagen). Plasmid
and primer details are provided in Supplementary Table
S1. The remaining steps were done essentially as previously
described (13). The wild-type or mutant DNA baits were
separately immobilized onto streptavidin-coated magnetic
beads (Dynabeads M-280, Life Technologies, using 300 g
of beads per 1.5 g of dsDNA) at room temperature for 3
h and washed with Buffer DW (Tris pH 8, 2M NaCl, 0.5
mM ethylenediaminetetraacetic acid (EDTA), 0.03% NP-
40) to remove unbound DNA. The DNA-conjugated strep-
tavidin beads were then blocked with Blocking Buffer (20
mM HEPES-NaOH, 0.05 mg/ml bovine serum albumin,
0.3M KCl, 0.02% NP-40, 5 mg/ml polyvinylpyrrolidone,
0.05 mg/ml glycogen and 2.5 mM dithiothreitol, DTT)
at room temperature for 1 h with rotation. Pre-clearing
of the nuclear protein extracts, prior to incubation with
DNA baits was done as follows: first, potassium glutamate
(to a final concentration of 10 mM) and one volume of
Buffer G (20 mM Tris pH 7.4, 10% Glycerol, 0.1 M KCl,
0.2 mM EDTA, 10 mM potassium glutamate, 0.04% NP-
40, 2 mM DTT, supplemented with protease and phos-
phatase inhibitor cocktails, Roche) containing 0.2 mg/ml
poly dA.dT or poly dI.dC were added to 0.5 mg of labelled-
or unlabelled-nuclear extract. Then, the extracts were incu-
bated separately with washed, unconjugated, streptavidin
beads for 1 h at 4◦C with rotation in order to remove any
non-specific binders to the beads. The unconjugated beads
were then removed by magnetic separation and the result-
ing pre-cleared nuclear extracts were incubated with the ap-
propriate DNA-conjugated, blocked, streptavidin beads for
3 h at 4◦C, with rotation. The wild-type or mutant DNA-
conjugated beads, with bound proteins, were washed four
times with Buffer G and the beads were then combined.
DNA-bound proteins were eluted by boiling in NuPAGE
LD buffer (Life Technologies) at 95◦C before being sep-
arated on a sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel. Bands were visualized by
coomassie staining and the entire lane was diced into 1
mm pieces and subjected to in-gel trypsin digestion. The di-
gested peptides were eluted and analysed by MS.
Mass spectrometry
All samples were analysed using anOrbitrapVelos (Thermo
Electron, Bremen, Germany) mass spectrometer. The di-
gested peptides were separated by nano-LC using an Ul-
timate 3000 RSLC and autosampler system (Dionex, Am-
sterdam, The Netherlands). Samples were concentrated
and desalted onto a micro C18 precolumn (500 m ×
2 mm, Michrom Bioresources, Auburn, CA, USA) with
H2O:CH3CN (98:2, 0.05% Trifluoroacetic acid (TFA) at 15
l/min. After a 4 min wash the pre-column was switched
(Valco 10 port valve, Dionex) into line with a fritless nano
column (75 m × ∼12 cm) containing C18 media (3
, 200 A˚ Magic, Michrom or 1.9 , 120 A˚ Dr Maisch,
Ammerbuch-EntringenGermany). Peptides were eluted us-
ing a linear gradient of H2O:CH3CN (98:2, 0.1% formic
acid) to H2O:CH3CN (64:36, 0.1% formic acid) at 200
nl/min over 36 min. High voltage (2000 V) was applied to
low volume union (Upchurch Scientific) and the column tip
positioned ∼0.5 cm from the heated capillary (T = 275◦C).
Positive ions were generated by electrospray and the Orbi-
trap operated in data dependent acquisition mode. A sur-
vey scan m/z 350–1750 was acquired in the Orbitrap (Res-
olution = 30 000 at m/z 400, with an accumulation target
value of 1 000 000 ions) with lockmass enabled. Up to the
ten most abundant ions (>5000 counts) with charge states
> +2 were sequentially isolated and fragmented within the
linear ion trap using collision induced dissociation with an
activation q = 0.25 and activation time of 10 ms at a target
value of 30 000 ions. M/z ratios selected for MS/ MS were
dynamically excluded for 30 s.
Mass spectrometry data analysis
All LC-MS/MS data were anaylsed using MaxQuant (ver-
sion 1.3.0.5 Max Planck Institute of Biochemistry, Martin-
sried, Germany). The analysis of protein identification and
quantifications was carried out as described by the software
user guide. Briefly, RAW files generated by Thermo mass
spectrometer were uploaded into MaxQuant software and
analysed using the following search parameter: (i) variable
modifications: Oxidation (M), Acetyl (Protein N-term); (ii)
fixed modification: Carbamidomethyl (C); (iii) labels: Argi-
nine (R) Label: 13C6, Lysine (K) label: 13C6; (iv) enzyme
specified was trypsin and allowing maximum two missed
cleavages. All spectra were search using Uniprot database
(UniProtKB/Swiss-Prot, release 2013) with common con-
taminants included. A one sample t––statistic for each pro-
tein was generated by first evaluating the heavy/light pep-
tide log-ratios matched to the heavy/light protein ratio
count, where ratio count is the number of peptides used for
quantitation (30). The peptide log-ratio is then divided by
the standard error, where ratio variability % is the standard
deviation of peptides. All the ratio values were generated
in MaxQuant. The following formula was used to yield the
t––statistic:




[(Ratio variability %) /100] /
√
Ratio HL count
Under the null hypothesis that there is no change in
abundance of the protein between the two populations and
under the assumption that the distribution of the peptide
log-ratios are normal. The P-value of each protein was
then calculated using the Student-t distribution. For protein
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abundance––gene expression correlations, absolute protein
amounts were calculated as the sum of all peptide peak in-
tensities divided by the number of theoretically observable
tryptic peptides (31). The log2 value of the normalized pro-
tein intensity was used to plot against microarray gene ex-
pression. Microarray gene expression data from leukaemic
cell lines samples were obtained from CellLineNavigator
(32). The raw expression files were pre-processed includ-
ing background subtractions, quantile normalization, log2
transformation and batch effect removal using Partek Ge-
nomics Suite software (Partek Inc). Expression of genes was
selected based on the corresponding probe with the max-
imum average expression across all samples. Correlations
between gene expression values and quantitative MS abun-
dance measurements were performed in ‘R’ and the line of
best fit obtained by performing linear modelling using the
‘lm’ package in ‘R’.
Chromatin immunoprecipitation
ChIP assayswere performed as previously described (29) us-
ing the following antibodies: ETV6 (Santa Cruz, sc-8546x),
IKZF1 (BD AF4984), PU.1 (Santa Cruz, sc-352X) or, as
control, non-specific goat IgG (Sigma, 15256). Quantita-
tive PCR was performed to measure the level of enrich-
ment at the ERG +85 enhancer region. A full list of primers
used in ChIP-qPCR is provided in Supplementary Table S1.
Data analysis was done using MxPro qPCR software (Ag-
ilent Techchologies) and relative expression levels were cal-
culated using a standard curve (range: 0.4–50 ng of the input
material). Enrichment values were normalized to IgG.
Stable transfection assays
Transfections of MOLT-4 and KG-1 cells (5–10 × 106
cells/pulse) were performed using standard electroporation
conditions (900 F / 220 V on a BioRad Gene Pulser
Xcell™). Cells were co-transfected with 10 g of linearized
plasmid DNA (wild-type pGL2p ERG+85 or mutants) and
1 g pGKNeo encoding the Neomycin resistant gene. Cells
were cultured under normal conditions. Geneticin (G418)
(Life Technologies) was added to stable transfected cells
48 h after electroporation at a concentration of 750 g/m
of media. After 15 days, 1 × 106 cells were harvested and
luciferase activity was measured using a microplate lu-
minometer (GloMax96, Promega) as previously described
(29).
Gene knockdown experiments and gene expression analyses
siRNA knockdowns of ETV6 and IKZF1 were performed
in a KG-1 cell line stably transfected with a pGL2p ERG
+85 reporter. siRNA transfections were performed using
the Neon® transfection system (Life Technologies). All
siRNA (purchased from Qiagen) were labelled with Cy3
using the Silencer siRNA labelling kit (Life Technologies)
and 0.3 M of Cy3-labelled siRNA was used per trans-
fection. One hour after electroporation, Cy3-positive cells
were isolated using a BD Influx™ cell sorter and allowed
to grow for 72 h. RNA was extracted using the RNeasy
Mini kit (Qiagen) and complementary DNA synthesis was
performed using standard methods as previously described
(29). Knockdown of target genes was measured by quanti-
tative real time-PCR. Relative expression levels were calcu-
lated using a standard curve (range: 0–50 ng) for each gene
and normalized against housekeeping genes as per estab-
lished guidelines (33).
Lentiviral-mediated shRNA knockdown vectors were
purchased from Sigma and the hairpins were subcloned
into a modified pLKO.1 vector in which the puromycin re-
sistance cassette was replaced with green fluorescent pro-
tein (GFP) . Lentiviral particles were produced by co-
transfecting 293T cells with the shRNA clone and pack-
aging plasmids (34). Viral supernatants were generated by
culturing the 293T producer cells in medium appropriate
for the target cells for 16 h and 0.45 m––filtered viral su-
pernatants were then used immediately for target cell trans-
duction. For MOLT-4 transductions, two rounds of trans-
duction were performed on sequential days. Cells were re-
suspended in viral supernatant supplemented with 8 g/ml
protamine and incubated at 37◦C until the following day.
After two rounds of transduction, cells were washed and
resuspended in RPMI supplemented with 10% FBS, 2 mM
glutamine and 100 U/ml penicillin/streptomycin and incu-
bated at 37◦C for a further 72 h prior to RNA extraction.
The transduction efficiency, as measured by the percentage
of GFP+ cells, was generally 95% or more.
Primary CD34+ isolation, transduction and OP-9 stro-
mal co-culture were done essentially as previously described
(35–37). Cord blood CD34+ cells were thawed and pooled,
then cultured overnight in IMDM supplemented with 20%
FBS, 2 mM glutamine, 50 g/ml gentamycin, 100 ng/ml
human stem cell factor (SCF, Peprotech), 50 ng/ml hrom-
bopoietin (TPO, Peprotech) and 100 ng/ml FLT3 ligand
(FLT3L, Peprotech). Two rounds of transduction were per-
formed on sequential days. Cells were resuspended in viral
supernatants supplemented with 8 g/ml protamine, 100
ng/ml SCF, 100 ng/ml TPO and 100 ng/ml FLT3L and
spun on RetroNectin (Takara) coated plates at 250 g for
90 min at 30◦C. Plates were then incubated at 37◦C until
the following day. After two rounds of transduction, cells
were washed and resuspended in fresh medium containing
cytokines and incubated at 37◦C for a further 72 h. GFP
positive cells were sorted using a FACS Aria IIIu (Bec-
ton Dickinson) and RNA was extracted immediately after
sorting. For assessment of proliferation potential of ETV6
knockdown cells in culture, transduced cells were grown in a
cytokine-driven medium essentially as previously described
(37). Aliquots of cells were collected at different time points
during a 6-day period and GFP expression status was as-
sessed by flow cytometry.
For CD34+ transduction experiments followed by OP-
9 stromal co-culture, a lentiviral shETV6 vector (Sigma-
Aldrich) was used to knock down ETV6. As a non-
targeting shRNA control, MISSION pLKO.1-puro Non-
Mammalian shRNA Control Plasmid was used. Virus pro-
duction was performed in HEK293TN cells using JetPEI
polyplus with pMD2.G (envelope plasmid), psPAX2 (pack-
aging plasmid) and MISSION control shRNA or MIS-
SION shETV6 vector (target plasmid) in 0.1/0.9/1 ratios.
CD34+ cord blood cells were brought into culture and
transduced the next day with the lentiviral viruses. Forty-
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eight hours after transduction, GFP expressing (i.e. trans-
duced) cells were co-cultured with OP9 stromal cells. An-
other 72 h later, transduced cord blood cells were sorted
based on GFP and hCD45 positivity on a BD FACSAria
II sorter.
Western blots
Proteins were separated on SDS-PAGE gels and transferred
onto nitrocellulose membranes using the iBlot® Gel Trans-
fer Device (Life Technologies) at 20V for 8 min. West-
ern blot analysis was performed using the following pri-
mary antibodies: ERG (Santa Cruz, sc-354x), ETV6 (Ab-
cam, ab64909), IKZF1 (BD, AF4984), PU.1 (Santa Cruz,
sc-352x), GATA2 (Santa Cruz, sc-9008x), RUNX1 (Ab-
cam, ab23980) and TOPO1 (BD Pharmingen, 556597). The
following secondary antibodies were used: polyclonal goat
anti-rabbit HRP (Darko, P0448), polyclonal rabbit anti-
mouse HRP (Darko, P0260), polyclonal rabbit anti-goat
HRP (Darko, P0449). Band detection and quantification
were performed using an ImageQuant LAS4000 machine
(GE Healthcare Life Sciences, Uppsala, Sweden).
AML patient data analysis
The raw expression data for cytogenetically normal AML
patients (38) was extracted and pre-processed using Partek
Genomics Suite (v6.6) including background subtrac-
tions, quantile normalization and log2 transformation. The
normalized expression levels were processed in Matlab
(R2015b) and Pearson’s linear correlation coefficient were
computed between different probesets/genes. The normal-
ized expression levels were further processed in Matlab
(R2015b) and Prism (v6.07) to calculate overall survival dif-
ferences using the Kaplan–Meier estimator. In case of sin-
gle gene analysis (i.e. ETV6 or IKZF1 alone), patient sub-
groups were first stratified by the mean expression of the
analysed gene. In case of multi-gene analysis, patient sub-
groups were first partitioned using the k-means clustering
algorithm with k = 2. Patient subgroups were then com-
pared using the Log-rank (Mantel-Cox) test and Kaplan–
Meier curves were generated using Prism.
RESULTS
Identifying binders of the ERG +85 enhancer in MOLT-4
cells using reverseChIP
The highly conserved ERG +85 stem cell enhancer, hence-
forth referred to as the +85 enhancer, contains consen-
sus motifs for a number of different transcription factors
(Figure 1A) and strongly drives the expression of ERG in
healthyHSPCs (28) as well as in T-ALL (22) andAML (29).
Mutational studies presented here (Figure 1B) and previ-
ously (22,29), have identified specific regions within the +85
enhancer that are necessary for full transcriptional activ-
ity in T-ALL and AML cells. Prior ChIP studies have re-
vealed that a heptad of transcription factors (FLI1, ERG,
GATA2/3, RUNX1, SCL, LYL1 and LMO2) binds the
+85 enhancer in healthy HSPCs as well as in T-ALL and
AML cells, including in the cell lines MOLT-4 and KG-
1 (2,22,28,29). However, the identities of the specific fac-
tors that bind within the sub-regions identified as impor-
tant for transcriptional activity of the +85 enhancer is un-
known. Furthermore, it remains unknown whether any ad-
ditional factors beyond the heptad also bind the +85 en-
hancer and might be involved in regulating high ERG ex-
pression in leukaemic cells.
In order to shed more light on these unknowns, we
adapted a recently developed, SILAC-based, quantitative
MS method (13) to interrogate the +85 enhancer. We mod-
ified the original protocol at various steps in order to im-
prove the sensitivity and workflow of the technique. First,
by using a nuclear protein extraction kit that efficiently
extracts nuclear proteins in a native, non-denatured form,
thereby preserving their functionality, we were able to cir-
cumvent the laborious nuclei preparation steps or a need
to dialyse away detergents and renature proteins that were
employed in the original protocol. Next, by using biotin-
labelled PCR primers to generate amplicons, we could
quickly generate biotinylated baits from a variety of ge-
nomic templates without requiring the in vitro re-annealing
of single-strandedDNA fragments that has been previously
employed. As presented later in this manuscript, this inno-
vation also enabled us to easily generate large baits from the
entire +85 enhancer in order to identify binders to the entire
enhancer region. At last, by directly eluting DNA-bound
proteins off streptavidin beads, we averted the need to per-
form restriction digests to release DNA (and DNA-bound
proteins) from the beads, a critical last step that is very sen-
sitive to buffer conditions and could adversely decrease elu-
tion yields. As outlined in Figure 1C, the method we have
refined (henceforth ‘reverseChIP’) involves generating bi-
otinylated wild-type or mutated DNA fragments of the +85
enhancer by PCR using biotin-tagged primers, followed by
immobilization of the amplicons onto streptavidin-coated
magnetic beads. The wild-type or mutant DNA-conjugated
beads are then incubated separately with metabolically-
labelled (‘heavy’) or unlabelled (‘light’) nuclear protein ex-
tracts, followed by stringent washes to remove non-specific
background proteins. The beads are then combined, DNA-
bound proteins eluted and fractionated by SDS-PAGE, en-
tire gel lanes cut into multiple pieces and an in-gel trypsin
digestion is performed. The digested peptides are then anal-
ysed by quantitative MS to identify specific binders to each
DNA fragment (Figure 1C).
As a proof-of-principle, we initially interrogated a region
of the +85 enhancer containing three tandem ETS-binding
motifs (E2, E3, E4, collectively 3×ETS), which when mu-
tated abrogates transcriptional activity of the enhancer in
MOLT-4 T-ALL cells (Figure 1B and (22)). Using PCR
primers flanking the 3×ETS motifs, we generated a 91 bp
wild-type fragment and a 75 bp mutant bait lacking the
3×ETS motifs (designated as ‘3×ETS’, Figure 1B) from
appropriate templates (listed in Supplementary Table S1)
to perform reverseChIP. To provide an additional level of
stringency in distinguishing truly specific binding from spu-
rious enrichment, we ran two parallel experiments: a for-
ward experiment where ‘heavy’ proteins were incubatedwith
wild-type bait and ‘light’ proteins were incubated with the
mutant bait; and a reverse experiment where the order was
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Figure 1. The ERG +85 stem cell enhancer and reverseChIP methodology. (A) Multiple sequence alignment of the highly conserved ERG +85 enhancer,
with human (Hs), mouse (Mm), dog (Cf) and opossum (Md) sequences, adapted from (22,29), is shown. The position of the +85 enhancer is shown relative
to the start of ERG for both human (hERG) and mouse (mERG), along with human and mouse conservation, at the top. The sequences highlighted in
black have 100% sequence conservation while the grey regions are less conserved. Consensus motifs for different transcription factors are also indicated,
including ETS (blue, E1, E2, E3 and E4), GATA (red, G1, G2), E-Box (yellow, EB1, EB2 and EB3) andMYB (magenta, M1 andM2). Predicted sequence
motifs are depicted on the right. (B) Mutational analysis of the +85 enhancer. The schematic on the left depicts the transcription factors motifs which were
present on the different +85 enhancer constructs that were tested in stable transfection assays in MOLT-4 (left) and KG-1 (right) cells. (C) Schematic of the
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swapped (i.e. ‘light’ proteins with wild-type bait and ‘heavy’
proteins with mutant bait). Approximately equal quanti-
ties of proteins were eluted in forward and reverse experi-
ments, as can be seen in a representative gel image (Fig-
ure 1D). To easily visualize binders of each bait, a two-
dimensional logarithmic plot of enrichment values for the
different binders in a forward and reverse experiment can
be plotted (Figure 1E). Factors enriched on the wild-type
fragment would have a log2 (‘heavy’/‘light’) ratio > 0 in
the forward experiment and a ratio < 0 in the reverse ex-
periment, thus falling within the bottom right quadran-
gle (Figure 1E); non-specific binders would have approxi-
mately equal ‘heavy’/‘light’ ratios in both experiments and
will therefore be present around the origin, within the cir-
cled region; while factors that are enriched on the mutant
bait would have a ratio < 0 in the forward experiment and
>0 in the reverse experiment, thereby falling within the top
left quadrangle in Figure 1E. Externally contaminating pro-
teins, such as keratin, would always be unlabelled (i.e. ‘light’
in both forward and reverse experiments) and consequently
lie in the bottom left quadrangle while false positives would
lie in the top right quadrangle.
Focusing on factors with known roles in transcrip-
tional regulation, we have identified ETV6, an ETS-family
transcription factor that is an essential regulator of nor-
mal haematopoiesis (39,40) but which is also mutated in
leukaemias including in an aggressive form of T-ALL
(41,42), as a specific binder of the 3×ETS region in MOLT-
4 cells (with log2 enrichment values 5.44 and −4.51 in the
forward and reverse experiments respectively and a P-value
for enrichment: 1.23×10−7, Figure 2A). This is the first re-
port to identify ETV6 binding at the +85 enhancer.We have
also identified the Ikaros zinc finger transcription factor,
IKZF1, another critical regulator of haematopoiesis (43)
which is also frequently mutated in ALL patients with a
high risk of relapse (44), as a factor enriched on the wild-
type bait (Figure 2A). Additionally, we detected the binding
of a closely related family member, Helios/IKZF2, on the
wild-type bait. Closer sequence analysis of the 3×ETS frag-
ment showed the previously missed presence of the IKZF1
core binding motif (GGGAA) within the region disrupted
on the mutant bait. IKZF1 and IKZF2 are known co-
interactors which bind DNA together in a complex (45,46),
and the nearly identical enrichment values for IKZF1 and
IKZF2 on the wild-type bait (log2 enrichment values for
IKZF1: 2.75 and −1.22 and IKZF2: 2.60 and −1.10, and
a P-value for enrichment: 1.06 × 10−5, Figure 2A) are con-
sistent with this. We also detected the binding of other pre-
viously known haematopoietic regulators, such as RUNX1,
CBFB, GATA3 and MYB. However, unlike ETV6 and
IKZF1 or IKZF2, these other factors were equally enriched
on both thewild-type andmutant baits and are therefore sit-
uated near the origin (Figure 2A), indicating that the dele-
tion of the 3×ETS motifs has not abrogated their bind-
ing sites. RUNX1 and CBFB bind DNA together as a het-
erodimeric transcriptional complex termed the core bind-
ing factor, with RUNX1 involved in direct DNA binding
(47,48). Consistent with this, we observed both these fac-
tors binding with very similar enrichment values in our re-
verseChIP experiment. The full list of binding proteins to
the 3×ETS bait is provided in Supplementary Table S2.
Another region within the +85 enhancer that is essen-
tial for full transcriptional activity contains an E-box and
an ETS-motif (‘EB1’ and ‘E1’ respectively, EB1E1 collec-
tively). By PCR, we generated a 116 bp wild-type bait and
a 92 bp mutant bait lacking the EB1E1 motifs (‘EB1E1’,
Figure 1B), which we used in reverseChIP. We have iden-
tified, for the first time, the BEN-domain containing pro-
tein BEND3 as a highly enriched binder of the wild-type
bait (P-value for enrichment: 2.83 × 10−14, Figure 2B).
BEND3 has been recently discovered to recruit the PRC2
complex to pericentromeric regions (49) and is implicated
in establishing higher-order chromatin structure (50).While
a DNA binding consensus motif (TCYAATHRGAA) has
been identified for aDrosophila melanogaster BEN-domain
containing nuclear co-repressor, Insensitive (51), no analo-
gous consensus motifs are known for BEND3 nor could we
find any matches to the Drosophila consensus motif within
the EB1E1 region. BEND3 has never previously been impli-
cated in regulating transcription of haematopoietic genes.
The full list of binding proteins to the EB1E1 bait is pro-
vided in Supplementary Table S2.
Interrogating the entireERG+85 enhancer region with rever-
seChIP
Having established that the reverseChIP method is capable
of discovering new transcription factors binding to small re-
gions of interest within the ERG +85 enhancer, we explored
whether the method could be extended to study the full
length enhancer, a genetically complex region larger than
300 bp containing binding sites for a number of transcrip-
tion factors (Figure 1A). In order to limit non-specific bind-
ing of proteins to DNA probes of interest, previous MS-
based studies of DNA binding factors had restricted the
analyses to 40–60 bpDNAprobes (13,17,19,52,53). Extend-
ing the capability of the method to study larger genomic
fragments would not only facilitate our characterization of
the entire repertoire of factors binding the ERG +85 en-
hancer, but would also lay the groundwork for future studies
of other less-well characterized genomic regions.
As a first step towards this, we generated biotinylated
wild-type and mutant baits of the entire ERG +85 enhancer
region by PCR. ReverseChIP was performed using a 327 bp
wild-type bait, spanning from EB1 to G2 (Figure 1A) and
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
reverseChIPmethod.Metabolically labelled (‘heavy’, Arginine-6 andLysine-8) or unlabelled (‘light’) cells were grown and nuclear protein extracts prepared.
The extracts were separately incubated with biotin-labelled wild-type or mutated DNA baits and conjugated onto streptavidin beads. The beads were then
washed, combined and bound proteins were eluted. Eluates were run on a sodium dodecyl sulphate-polyacrylamide gel electrophoresis gel, the lane cut
into multiple pieces and proteins digested in-gel with trypsin. Peptides were recovered and analysed by mass spectrometry (MS). (D) A representative gel
indicating equal protein yields in the eluates from forward and reverse experiments. The lane was cut into slices (putative cut sites indicated as dotted lines).
(E) A schematic illustrating enrichment biplots generated from parallel, order-swapped, reverseChIP experiments with the location of binders based on
specificity of binding.
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Figure 2. ReverseChIP on two regions within the ERG +85 enhancer inMOLT-4 cells. (A) The enrichment biplot on the left shows the results from parallel
reverseChIP experiments on the 3×ETS region in MOLT-4 cells. Representative mass spectra for ETV6 (for the exemplary peptide: DDVAQWLK) is
shown on the right to illustrate specific enrichment on the wild-type bait in both forward and reverse experiments. (B) ReverseChIP results of theEB1E1
region in MOLT-4 cells. The representative mass spectra on the right (for an exemplary peptide: EIVQQSLSVGNFAAR) illustrates specific enrichment
for BEND3 on the wild-type bait.
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a 286 bp mutant fragment lacking the 3×ETS and EB1E1
motifs (3×ETSEB1E1, Figure 1B).We sought to deter-
mine whether the identity of the specific binders previously
identified on the individual small fragments would remain
consistent in the context ofmanymore potential binders. As
seen in Figure 3A, we have identified most of the previously
known binders (22) of the ERG +85 enhancer in MOLT-4
cells originally discovered by conventional ChIP (including
SCL/TAL1, LMO2, ERG, FLI1, RUNX1 and GATA3).
In order to better distinguish specific binders from spuri-
ous enrichment, we again performed parallel forward and
reverse reverseChIP experiments. In addition to the previ-
ously known binders above, we have also identified all of the
novel specific binders of the wild-type bait that we identi-
fied by doing reverseChIP on smaller baits (ETV6, IKZF1,
IKZF2 and BEND3, all P < 0.01, Figure 3A). This result
shows that the binding of specific factors to the wild-type
bait were unaffected by the binding of other factors on the
large bait. In addition, the signal of specific binders enriched
on the wild-type bait comes through clearly, despite the in-
creased possibility for noise emanating from non-specific
binders.
To verify the MS findings by an orthogonal method, we
performed DNA affinity capture of nuclear proteins using
the wild-type or mutant +85 enhancer fragments as baits
and probed the eluted proteins using primary antibodies
against some of the specific proteins identified byMS. Con-
sistent with theMS results, we detect specific enrichment for
ETV6 and IKZF1 on the wild-type bait compared to the
mutant bait, whereas RUNX1 binds equally to both baits
(Figure 3B). To rule out that reverseChIP is biased towards
detecting the binding of only themost abundantly expressed
transcription factors, we performed quantitative MS to de-
termine the abundance of all proteins in the nucleoplasm,
the input material for our reverseChIP experiments. We as-
sessed the correlation between protein abundance and gene
transcription, using publicly available microarray data from
MOLT-4 cells in CellLineNavigator (32). As shown in Fig-
ure 3C, there is generally a good correlation between pro-
tein levels and gene expression (R2 = 0.545). However, there
is no correlation between the identity of factors detected
as binders of the ERG +85 enhancer by reverseChIP and
their abundance in nucleoplasm (Figure 3C). For example,
BEND3 is a factor that is clearly enriched on the wild-type
3×ETS bait and 22 unique peptides were detected in MS
(Supplementary Table S2), however its abundance is rela-
tively low compared to the other detected binders (Figure
3C). ETV6, another factor enriched on the wild-type bait
for which 17 unique peptides were detected in MS, is only
moderately abundant compared to other binders (Figure
3C). Conversely, none of the most abundant nuclear pro-
teins were identified by reverseChIP as specific binders of
the +85 enhancer. Our data therefore indicates that the re-
verseChIP assay is pulling down factors that specifically
bind the region of interest rather than merely identifying
abundant transcription factors.
While the reverseChIP assay identifies potential binders
of a naked DNA sequence in vitro, the chromatin environ-
ment around the cognate region can influence the binding
of a transcription factor inside cells.We therefore performed
a conventional ChIP assay to ascertain whether ETV6 and
IKZF1 bind the +85 enhancer within MOLT-4 cells. Con-
sistent with our reverseChIP data, we find enrichment for
both ETV6 (2.2×-fold) and IKZF1 (3.16×-fold) at the +85
enhancer (Figure 3D), showing for the first time that these
factors bind the ERG enhancer within cells.
ETV6 and IKZF1 are also novel binders of the ERG +85 en-
hancer in AML cells
ERG is also a potent oncogene in AML and we have pre-
viously shown that its high expression in AML cells is de-
pendent on the binding of a heptad of transcription factors
to the +85 enhancer (29). However, it is unknown if addi-
tional factorsmight also bind this region inAMLcells. Hav-
ing established that we could interrogate the full-length +85
enhancer fragment with reverseChIP, we proceeded to iden-
tify the complement of transcription factors that can bind
this region in AML cells. As the 3×ETS and EB1E1 regions
are also necessary for full transcriptional activity of the +85
enhancer in the KG-1 AML cell line (Figure 1B and (29)),
we performed reverseChIP using the same 327 bp wild-type
+85 enhancer and the 286 bp mutant 3×ETS EB1E1
fragments as before, using SILAC-labelled (‘heavy’) and un-
labelled (‘light’) nuclear protein extracts prepared fromKG-
1 cells.
Similar to T-ALL cells, we found that ETV6 binding was
strongly enriched on the wild-type enhancer fragment in
AML cells (log2 enrichment values of 3.39 and −2.57 in
the forward and reverse experiments respectively, P-value
for enrichment: 1.4 × 10−9, Figure 4A). We also observed
enrichment for IKZF1 and PU.1 on the wild-type frag-
ment, and identified most of the previously known binders
of the +85 enhancer identified by ChIP (29), including
ERG, FLI1, LYL1, RUNX1 and GATA2 (all P < 0.01).
Consistent with the MS findings, affinity capture of nu-
clear proteins followed by western blots against specific pro-
teins show enrichment in binding for ETV6 and IKZF1 on
the wild-type probe, whereas a non-specific binder such as
GATA2 bound equally to both baits (Figure 4B). Addition-
ally, we tested for any correlation between binders identi-
fied by reverseChIP and protein abundance. We once again
performed quantitativeMS of nuclear protein extracts from
KG-1 cells and determined that there was an overall good
correlation with gene expression levels in KG-1 cells from
CellLineNavigator (R2 = 0.519, Figure 4C). However, as
in MOLT-4 cells, we did not find any correlation between
the identity of binders by reverseChIP and their abundance
(Figure 4C), indicating once again that we are not simply
identifying the most abundant proteins but rather specific
potential binders of the +85 enhancer in KG-1 nuclear ex-
tracts. Lastly, by conventional ChIP, we validated the bind-
ing of ETV6 and IKZF1 at the ERG +85 locus within cells,
thereby identifying for the first time that these factors are
true binders of this region within AML cells (Figure 4D).
ETV6 and IKZF1 are bona fide transcriptional regulators of
heptad target genes, including ERG, in leukaemic cells and in
healthy HSPCs
To determine whether ETV6 and IKZF1 regulate high
ERG expression in leukaemic cells, we performed siRNA-
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Figure 3. Identification of binders of the composite 321 bp ERG +85 enhancer fragment in MOLT-4 cells. (A) The enrichment plot on the left plots
log2 ratios for the abundance of the different factors bound to the wild-type (W.T.) bait compared to the mutant 3×ETSEB1E1 (Mut.) bait. The
enrichment biplot on the right shows log2 (heavy/light) ratios of binders from parallel, order-swapped, reverseChIP experiments. (B) Western blot analyses
of factors bound to theW.T. andMut. enhancer fragments. Input (I), Unbound (U) and Bound (B) fractions are shown. Curly brackets indicate differently
migrating isoforms for the relevant proteins. (C) Scatterplot of protein abundance from quantitative MS versus microarray gene expression levels from
CellLineNavigator (32) for all identified proteins in MOLT-4 nuclear extracts. The dotted line shows a line of best fit and an R2 value from Spearman
correlation is also indicated. The identities of selected transcription factors identified as binders of the +85 enhancer in MOLT-4 cells is also shown. (D)
ChIP-qPCR showing enrichment, relative to IgG, of ETV6 and IKZF1 at the +85 enhancer locus in vivo. Error bars represent standard deviation from
replicates.
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Figure 4. Identification of binders of the ERG +85 enhancer in KG-1 cells. (A) The enrichment plot on the left plots log2 ratios for the abundance of the
different factors bound to the wild-type (W.T.) bait compared to the mutant3×ETSEB1E1 (Mut.) bait. The enrichment biplot on the right shows log2
(heavy/light) ratios of binders from parallel, order-swapped, reverseChIP experiments. (B) Western blot analyses of factors bound to the wild-type (W.T.)
and mutant (Mut.) enhancer fragments. Input (I), Unbound (U) and Bound (B) fractions are shown. Curly brackets indicate differently migrating isoforms
for the relevant proteins. (C) Scatterplot of protein abundance from quantitative MS versus microarray gene expression levels from CellLineNavigator (32)
for all identified proteins in KG-1 nuclear extracts. The dotted line shows a line of best fit and anR2 value from Spearman correlation is also indicated. The
identities of selected transcription factors identified as binders of the +85 enhancer in KG-1 cells is also shown. (D) ChIP-qPCR enrichment of factors,
relative to IgG, at the +85 enhancer locus in vivo. Error bars represent standard deviation from replicates.
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mediated knockdown experiments of both factors in KG-
1 cells. We generated a KG-1 reporter cell line wherein
the transcription of the luciferase gene was controlled by
the ERG +85 enhancer. Cells were transfected with Cy3-
labelled siRNA against ETV6, IKZF1 or a scrambled con-
trol, FACS sorted for Cy3-positive cells and used to deter-
mine luciferase activity and gene expression by quantita-
tive PCR. siRNA knockdown of either ETV6 or IKZF1 led
to >50% decrease in luciferase activity compared to con-
trol cells treated with scrambled siRNA (P < 0.05, Figure
5A). Additionally, the expression of the endogenous ERG
gene was decreased by∼30% in cells where ETV6 or IKZF1
were knocked down, compared to scrambled control cells
(P < 0.05, Figure 5B). Additionally, shRNA mediated sta-
ble knockdowns in MOLT-4 cells of ETV6 and IKZF1 also
reduced ERG transcription (Figure 5C), indicating for the
first time that ETV6 and IKZF1 are transcriptional regu-
lators of ERG in leukaemic cells. Leukaemic cells are espe-
cially sensitive to themodulation ofERG levels, with knock-
downs leading to increased cell death in MOLT-4 (22), Ju-
rkat (54) and REH cells (54). We therefore suspect the re-
sults here might be an underestimation of the actual de-
crease inERGmRNA levels upon knockdown ofETV6 and
IKZF1.
Previous studies have shown that the binding of the hep-
tad of transcription factors to the +85 enhancer is also im-
portant for high ERG expression in healthy HSPCs (2,28).
We sought to determine if ETV6 and IKZF1 might repre-
sent additional, as yet unknown, regulators of ERG tran-
scription alongside the heptad in healthy HSPCs. We per-
formed ChIP experiments of ETV6 and IKZF1 in primary
human CD34+ HSPCs. We observed enrichment for both
factors at the ERG +85 enhancer compared to a nega-
tive control region (LMO2 Neg, Figure 5D). The +85 stem
cell enhancer is one of a number of haematopoietic en-
hancers that are bound by the heptad in HSPCs (2,55).
Other haematopoietic enhancers bound by the heptad in-
clude HHEX +1 (56), GATA2 +3.5 (57), LMO2 -25 (58),
RUNX1 +23 (59), TAL1 +40 (60), FLI1 -15 (56) and the
LYL1 promoter (61). As with the ERG +85 enhancer, we
observed an enrichment for ETV6 and IKZF1 at these re-
gions (Figure 5D). To validate that ETV6 and IKZF1 regu-
late the transcription of other heptad genes, we performed
shRNA-mediated stable knockdowns of ETV6 and IKZF1
in primary HSPCs. A two-fold reduction in ETV6 resulted
in reduced transcription of a subset of heptad target genes
we tested (GATA2 and TAL1, Figure 5E) as well as a 50%
reduction in IKZF1 (Figure 5E). Two-fold reduction of
IKZF1 also led to the transcriptional down-regulation of
a subset of heptad target genes, including GATA2, RUNX1
and TAL1 (Figure 5E). However, unlike in leukemic cells,
we only observed a slight reduction in ERG transcription
(∼12.3% compared to a control luciferase knockdown, Fig-
ure 5E) in healthyHSPCs uponETV6 knockdown and con-
versely, an increase in ERG transcripts upon IKZF1 knock-
down (Figure 5E).
As the heptad is known to form a robust and highly
stable network that is resistant to noisy perturbations in
hematopoietic stem cells (62), we reasoned that the effects of
knockdowns might require a longer time to manifest more
pronouncedly. Since ETV6 knockdowns for 72 h hinted at
a slight reduction in ERG transcription (Figure 5E), we
investigated whether prolonged ETV6 knockdown would
result in a more marked effect. We performed lentiviral-
mediated shRNA knockdown of ETV6 in primary healthy
HSPCs and maintained the transduced cells for five days
using an OP9-based stromal co-culture setup (35,36), be-
fore sorting GFP+ CD45+ cells for analyses. We observed
that sustained knockdown of ETV6 led to a robust de-
crease in ERG and in five of the remaining six heptad
members (FLI1, GATA2, TAL1, LYL1 and LMO2, Figure
5F), as well as of IKZF1. Additionally, we also assessed
whether prolonged ETV6 knockdown might have any pro-
liferative consequences on healthy HSPCs. Using a compet-
itive culture assay in which ETV6 knockdown (GFP+) cells
were cultured together with control (GFP−) cells contain-
ing wild-type levels of ETV6, we were unable to observe
any statistically significant changes in the proportions of
GFP+ cells compared to control knockdown (Figure 5G).
Our data shows that ETV6 knockdown per se does not im-
pair the proliferation of cells. However, despite multiple at-
tempts, we were unable to achieve a >50% reduction of
ETV6. Auto-regulatory networks are bistable and can re-
versibly shift from OFF to ON and ON to OFF by varying
expression levels of individual components belowor above a
threshold of expression (62). It is possible that the inability
to propagate cells with lower levels of ETV6, which is es-
sential for the survival of hematopoietic stem or progenitor
cells (40) was due to switching OFF of this auto-regulatory
stem cell network and impaired cell proliferation.
In summary, we have discovered that ETV6 and IKZF1
are bona fide transcriptional regulators of a number of
heptad-regulated haematopoietic genes, including ERG, in
leukemic cells as well as in healthy HSPCs.
Increased ETV6 and IKZF1 expression is associated with
poor prognosis in AML
We have previously determined that an open chromatin
state of the ERG +85 enhancer and high expression of the
heptad factors that bind within this region are predictive
of poor clinical outcomes in cytogenetically normal AML
(CN-AML) patients (29). We investigated the correlation
in expression between ETV6, IKZF1 and members of the
heptad in this cohort of CN-AML patients, for whom gene
expression and matched clinical data were both available
(38). We observed that there was positive correlation (r:
0.24–0.36), with high statistical significance (P < 0.01), be-
tween the expression of ETV6 and five members of the hep-
tad (ERG, FLI1, GATA2, RUNX1 and LYL1), as well as
IKZF1 in these patients (Figure 6A). Therewas a slight anti-
correlation with the expression of TAL1 and no correlation
with LMO2 expression (Figure 6A). IKZF1 expression, on
the other hand, is positively correlated with ETV6 and four
heptad factors (ERG, FLI1, LYL1 and LMO2, r: 0.18–3),
while being negatively correlated withGATA2,RUNX1 and
TAL1 (Figure 6B).
Given the correlation in expression between
ETV6/IKZF1 and the heptad, we tested the clinical
implications of high expression of ETV6 and IKZF1 on
overall survival of AML patients. We stratified patients
based on their relative expression of ETV6 alone, IKZF1
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Figure 5. ETV6 and IKZF1 regulateERG expression. (A andB) KG1 cells were transfected with Cy3-labelled scrambled siRNA (control), ETV6 siRNA (si
ETV6) or IKZF1 siRNA (si IKZF1). Cy3-positive cells were flow sorted after transfection, grown for 72 h and used in assays. (A) Stable transfection assay,
measuring luciferase activity in vector only (pGL2P) or in conjunction with the +85 enhancer (pGL2P +85). *: P < 0.05, two-tailed t-test, in comparison
with scrambled control (Scr.). (B) Examination of endogenous ERG expression levels in KG1 cells treated with siRNA by quantitative real-time PCR. *:
P < 0.05, n.s.: P > 0.05, two-tailed t-test, compared to control and error bars represent standard deviation from technical replicates. (C) Examination
of endogenous ERG expression levels in MOLT-4 cells following shRNA-mediated knockdowns of ETV6 (top panel) and IKZF1 (bottom panel) by
quantitative real-time PCR. *: P < 0.05, n.s.: P > 0.05, two-tailed t-test, compared to control and error bars represent standard deviation from technical
replicates. (D) ChIP-qPCR enrichment of ETV6 and IKZF1 in healthy CD34+ HSPCs at well characterized hematopoietic enhancers that are also heptad
targets. LMO2 neg is a negative control region that it not bound by the heptad. Error bars represent standard deviation from replicates. (E) Normalized
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alone or ETV6 and IKZF1 in combination and investigated
differences in overall survival. As shown in Figure 6C, the
relative expression of neither of these two factors, singly or
together, were sufficient to segregate patients. However, the
combination of high ETV6, IKZF1 and ERG expression
stratified patients efficiently, with high expression of all
three factors associated with poorer overall survival (E, I,
ERG, P-value = 0.0375, Figure 6D). Further factoring in
the high expression of all seven heptad factors together with
ETV6 and IKZF1 additionally improves the stratification
(E, I, Heptad: P-value = 0.0046, Figure 6D). Our data
therefore indicates that ETV6 and IKZF1 are previously
unknown components of a densely interconnected network
of heptad transcription factors that regulate the expression
of a number of important hematopoietic genes and whose
high expression in AML is associated with poor prognosis.
DISCUSSION
In order to determine the full complement of transcrip-
tional regulators mediating high expression of ERG in
leukaemic cells, we adapted and refined a recently devel-
oped quantitative proteomics-basedmethod (13). By apply-
ing reverseChIP to identify potential binders of the ERG
+85 stem cell enhancer in T-ALL and AML cells, we dis-
covered two new factors, ETV6 and IKZF1. We have used
conventional ChIP to validate that these potential binders
truly interact with the +85 enhancer within cells. Our data
also indicates that these factors promote high ERG expres-
sion in leukaemic cells, as the knockdown of each factor re-
duced endogenous ERG transcription. In addition, we also
demonstrated that these factors regulate the expression of
a number of genes of the highly interconnected heptad of
transcription factors in healthy CD34+ HSPCs. Finally, we
have shown that the high expression of ETV6 and IKZF1,
in combination with the heptad, confers poor overall prog-
nosis in AMLpatients. In doing so, we have thus established
the utility of the reverseChIP method as an effective means
to discover novel transcriptional regulators of genes of dis-
ease relevance. Furthermore, we have extended the capabil-
ity of the method beyond small (<60 bp) DNA fragments
(13,17,19,52,53), using it to successfully interrogate the full-
length ERG +85 enhancer, a complex 321 bp region con-
taining binding sites for multiple transcription factors.
The reverseChIP method we present here is general
enough to be translatable to other genomic regions of in-
terest, including enhancers, promoters or mutated genomic
regions identified in genome-wide studies. The recent devel-
opment of high-throughput variations of the technique will
also enable it to be applied to simultaneously screen a large
number of regions of interest, such as multiple single nu-
cleotide polymorphisms (SNPs) identified in GWAS stud-
ies (17,52). The SILAC-based quantitative proteomics we
employed here requires culturing of cells in media contain-
ing labelled amino acids, which limits its direct utilization
for studying primary cells or other cell types that are diffi-
cult to maintain in culture. However, alternative chemical
labelling methods such as isobaric tags for relative and ab-
solute quantitation/iTRAQ (63) or stable isotope dimethyl
labelling (64), which don’t require culturing of cells in spe-
cialized media could be utilized in such cases (52). Recent
advances in label-free quantitative proteomics also make
it feasible to quantify the abundance of specific binding
proteins from extracts of primary cells without necessitat-
ing any labelling (65). Despite its advantages, we envisage
the reverseChIP method as a complement to, rather than
as a competitor of, ChIP. Both methods have their rela-
tive strengths, affording each its rightful place in the molec-
ular toolkit used in studying protein–DNA interactions.
While we have been able to optimize nuclear protein extrac-
tions and MS detection, sample consumption remains high
and we require ∼20 million cells to reliably perform rever-
seChIP. In contrast, highly sensitive ChIP methods such as
iChIP (66) and nanoChIP (67) enable binding of factors
to be detected in as few as 500 cells, permitting ChIP to
be applied to studying very rare populations of cells. Fur-
thermore, as reverseChIP relies on the binding of factors
to naked DNA in vitro, we cannot exclude the possibil-
ity that factors whose DNA binding is influenced by spe-
cific chromatin modifications and/or DNA modifications
might be missed being detected (i.e. false negatives). As it
is performed in vivo within the context of chromatin, ChIP
does not have this limitation. Techniques that incorporate
chromatin-assembled DNA baits (16) or methods capable
of isolating specific regions of in vivo chromatin along with
bound proteins, such as PICh (68) and CHAP-MS (69),
could also circumvent these limitations but are less straight-
forward to perform than reverseChIP.
The ability of transcription factors to modulate gene ex-
pression is regulated at a number of levels, including ac-
cessibility to their cognate binding site on DNA, interac-
tions with specific co-factors and post-translational mod-
ifications on the proteins. Here, we have discovered that
ETV6 and IKZF1 both contribute to high ERG expres-
sion in leukaemic cells. IKZF1 is a dual-functional tran-
scriptional regulator that can activate or repress genes,
as well as create favourable or repressive chromatin envi-
ronments, depending on the genomic locus (70). In AML
and T-ALL cells, our knockdown experiments indicate that
IKZF1 acts as a transcriptional activator of ERG, while
in healthy HSPCs it acts as a repressor. As IKZF1’s op-
posing transcriptional roles have been linked to its interac-
tions with specific co-factors, including the chromatin re-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
expression values from quantitative real-time PCRmeasurement of heptad target genes in primary cord blood CD34+ HSPCs following shRNA-mediated
knockdowns ofETV6 (top panel) or IKZF1 (bottompanel). * denotes genes withP< 0.05, two-tailed t-test, compared to control luciferase knockdown.All
other genes were non-significant (i.e.P> 0.05) and error bars represent standard deviation from technical replicates. (F) Normalized expression values from
quantitative real-time PCR measurement of heptad target genes in GFP+CD45+ sorted primary cord blood CD34+ HSPCs following 5 days of stromal
co-culture after shRNA-mediated knockdown of ETV6. * denotes genes with P < 0.05, two-tailed t-test, compared to control luciferase knockdown. All
other genes were non-significant (i.e. P> 0.05) and error bars represent standard deviation from technical replicates. (G) Flow cytometry-based assessment
of the maintenance of GFP+ primary cord blood CD34+ HSPCs in cytokine-containing media following shRNA-mediated knockdown of ETV6. n.s.: P
> 0.05, two-tailed t-test, compared to control luciferase knockdown and error bars represent standard deviation from technical replicates.
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Figure 6. The roles of ETV6 and IKZF1 in leukaemogenesis. (A) Representative gene expression correlation plots between ETV6 and a number of heptad
genes in cytogenetically normal AML (CN-AML) patients. Pearson correlation values (r) and associated P-values are also indicated. The bubble plots on
the right summarize pairwise correlations between ETV6 and all members of the heptad as well as IKZF1, with the corresponding Pearson correlation
indicated on the y-axis and the size of bubble indicating the P-value. Points above the dotted line indicate positive correlation, while points below suggest
negative correlation. (B) Representative gene expression correlation plots and bubble plot between IKZF1 and heptad genes. (C) Kaplan–Meier survival
curves for overall survival (OS) in cytogenetically normal AML patients segregated based on high or low expression of ETV6 alone (top panel), IKZF1
alone (middle panel) orETV6 and IKZF1 combined (bottom panel). The indicatedP-values were generated from a log-rank test. (D) Kapla–Meier survival
curves for overall survival (OS) in cytogenetically normal AML patients segregated based on high or low expression of ETV6, IKZF1 and ERG only (E,
I, ERG) or for ETV6, IKZF1 and the heptad (E, I, Heptad). The grey bars indicate all the survival curves illustrated in (C), overlaid for comparison. The
indicated P-values were generated from a log-rank (Mantel–Cox) test.
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modelling complex NuRD (71,72), it is possible that its as-
sociation with different co-factors in leukaemic cells mod-
ulates its function aberrantly. In this context, it is interest-
ing to note that in B-cell precursor ALL, concurrent intra-
genic deletion of ERG in the background of IKZF1 muta-
tions confers better patient outcomes (73), while in BCR-
ABL B-cell precursor ALL, IKZF1mutations confer worse
prognosis (74). Our data would predict that IKZF1 muta-
tions in B-ALL lead to increased ERG expression, in line
with our observations in healthyHSPCs, thereby conferring
poor prognosis. However, a concurrent intragenic deletion
of ERG would compensate for the resultant transcriptional
upregulation, leading to the better outcomes reported.
ETV6, on the other hand, has a well-studied role in nor-
mal haematopoiesis as a transcriptional repressor of genes
(75), though it functions as a transcriptional activator of
ERG and other heptad target genes. However, like IKZF1,
ETV6 too interacts with awide array of co-factors including
the MYST-family histone acetyltransferase TIP60/KAT5
(76), a known co-activator of genes (77–79). It is there-
fore entirely feasible that, just like IKZF1, ETV6 could be
a context-dependent transcriptional regulator with oppos-
ing activating and repressing roles at different genes. Such
a scenario is not inconceivable: the well-studied transcrip-
tional activator MYB, for example, directly repress almost
as many genes as it activates in myeloid cells (80). Intrigu-
ingly, transcriptional repression by MYB is additionally re-
liant on its interaction with p300, a known co-activator of
MYB (80). We have previously shown that the stem cell-like
transcriptional program driven by the heptad is active in
NPM1 mutation negative CD34+ AMLs (29) and is mutu-
ally exclusive with theHOX/MYC signatures ofNPM1mu-
tant and MLL-mutated leukaemias (81,82). Whereas our
data support a role for functional ETV6 in cooperating with
the heptad, it is noteworthy that loss of function ETV6mu-
tations (∼ 1.1% of all AML) is frequently associated with
NPM1 mutations (∼ 23%, (83)) suggesting they arise in a
very distinct subset of AML. It also does not preclude the
emergence of leukaemia in the context of germ-line loss
of function ETV6 mutations (in pre-B ALL, (84)), which
may cooperate with other mutations to generate their own
network structure that drives self-renewal of leukemic stem
cells. Furthermore, our findings that ETV6 binds strongly
to the 3×ETS motif of the ERG +85 enhancer raises an
interesting question as to why this particular factor is en-
riched, when potentially a number of different transcrip-
tion factors all belonging to the ETS family could all bind
there. It is likely that the local chromatin environment, pres-
ence of other bound factors, specific DNA sequence around
the bound site and post-translational protein modifications
could all be further potential determinants for which partic-
ular factor binds at a given genomic locus. Future genome-
wide studies of ETV6 and IKZF1 will be required to de-
termine the exact role these factors play, together with the
heptad, in initiating and/or maintaining stem cell-like tran-
scriptional regulatory networks in healthy stem cells and in
leukaemic cells.
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